Quick Answer
Aligos Therapeutics, Inc. reported Total Revenue of $2.19 million for fiscal year 2025.
Aligos Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $2.19M -39.5% |
$3.61M -41.7% |
$6.19M | — | — | — |
| Revenue (ASC 606) | $2.19M -39.5% |
$3.61M -41.7% |
$6.19M | — | — | — |
| Net Income | -$24.19M +81.6% |
-$131.21M -49.6% |
-$87.68M +8.7% |
-$96.05M +25.2% |
-$128.33M -18.2% |
-$108.54M -107.7% |
| Diluted EPS | -$2.45 +88.3% |
-$20.94 +38.8% |
-$34.20 -1420.0% |
-$2.25 | — | — |
| Total Assets | $88.53M +26.3% |
$70.09M -53.7% |
$151.53M +3.3% |
$146.69M -37.7% |
$235.37M -11.3% |
$265.30M +81.1% |
| Cash and Equivalents | $18.30M -50.5% |
$37.00M -72.7% |
$135.70M +66.8% |
$81.35M -56.5% |
$186.82M -15.2% |
$220.38M +216.8% |
| Stockholders Equity | $53.55M +284.8% |
-$28.97M -131.5% |
$92.08M -11.4% |
$103.90M -43.8% |
$184.73M -16.0% |
$220.04M +439.1% |
| R&D Expense | $69.45M -1.2% |
$70.27M -3.8% |
$73.04M -14.1% |
$85.08M -18.3% |
$104.15M +30.4% |
$79.89M +81.4% |
| Operating Income | -$87.98M +1.3% |
-$89.15M -1.2% |
-$88.13M +9.7% |
-$97.58M +24.0% |
-$128.32M -31.2% |
-$97.83M -81.0% |
| Shares Outstanding | 6.18M -92.3% |
79.90M +2559.9% |
3.00M -93.0% |
42.92M +0.5% |
42.69M +12.0% |
38.12M +870.5% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $741.0K | -40.7% | -23.2% |
| Revenue (ASC 606) | September 30, 2025 | $741.0K | -40.7% | -23.2% |
| Net Income | September 30, 2025 | -$31.54M | -63.8% | -98.8% |
| Diluted EPS | September 30, 2025 | -$3.04 | +1.0% | -98.7% |
| Total Assets | September 30, 2025 | $109.76M | +24.1% | -18.5% |
| Cash and Equivalents | September 30, 2025 | $41.95M | +18.7% | +124.8% |
| Stockholders Equity | September 30, 2025 | $71.83M | +43.4% | -29.5% |
| R&D Expense | September 30, 2025 | $23.94M | +42.7% | +71.3% |
| Operating Income | September 30, 2025 | -$28.36M | -40.9% | -52.7% |
| Shares Outstanding | September 30, 2025 | 6.15M | +85.1% | +0.0% |
- Aligos Therapeutics, Inc. reported Total Revenue of $2.19 million for fiscal year 2025.
- Aligos Therapeutics, Inc. showed a decrease of -39.5% in Total Revenue compared to the prior fiscal year.
- Aligos Therapeutics, Inc. reported Revenue (ASC 606) of $2.19 million for fiscal year 2025.
- Aligos Therapeutics, Inc. showed a decrease of -39.5% in Revenue (ASC 606) compared to the prior fiscal year.
- Aligos Therapeutics, Inc. reported Net Income of -$24.19 million for fiscal year 2025.
- Aligos Therapeutics, Inc. showed an increase of +81.6% in Net Income compared to the prior fiscal year.
- Aligos Therapeutics, Inc. reported Diluted EPS of $2.45 per share (loss) for fiscal year 2025.
- Aligos Therapeutics, Inc. showed an increase of +88.3% in Diluted EPS compared to the prior fiscal year.
- Aligos Therapeutics, Inc. reported Total Assets of $88.53 million for fiscal year 2025.
- Aligos Therapeutics, Inc. showed an increase of +26.3% in Total Assets compared to the prior fiscal year.
- Aligos Therapeutics, Inc. reported Cash and Equivalents of $18.30 million for fiscal year 2025.
- Aligos Therapeutics, Inc. showed a decrease of -50.5% in Cash and Equivalents compared to the prior fiscal year.
- Aligos Therapeutics, Inc. reported Stockholders Equity of $53.55 million for fiscal year 2025.
- Aligos Therapeutics, Inc. showed an increase of +284.8% in Stockholders Equity compared to the prior fiscal year.
- Aligos Therapeutics, Inc. reported R&D Expense of $69.45 million for fiscal year 2025.
- Aligos Therapeutics, Inc. showed a decrease of -1.2% in R&D Expense compared to the prior fiscal year.
- Aligos Therapeutics, Inc. reported Operating Income of -$87.98 million for fiscal year 2025.
- Aligos Therapeutics, Inc. showed an increase of +1.3% in Operating Income compared to the prior fiscal year.
- Aligos Therapeutics, Inc. reported Shares Outstanding of 6.18 million shares for fiscal year 2025.
- Aligos Therapeutics, Inc. showed an increase of +59.9% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: